Evaluation of in vitro and in vivo activity of benzindazole-4,9,-quinones against cryptosporidium parvum

Journal of Antimicrobial Chemotherapy

Volumn 50, Issue 6, 2002, Pages 975-980

  Kayser, Oliver ^a   Water, W Ray ^b   Woods, Keith M ^c   Upton, Steve J ^c   Keithly, Janet S ^d   Laatsch, Hartmut ^e   Kiderlen, Albrecht F ^f  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b NATIONAL ANIMAL DISEASE CENTER   (United States)

^c KANSAS STATE UNIVERSITY   (United States)

^d WADSWORTH CENTER   (United States)

^e UNIVERSITY OF GÖTTINGEN   (Germany)

^f ROBERT KOCH INSTITUTE   (Germany)

Author keywords

Antiprotozoal; Benzindazole 4,9 quinones; Cryptosporidium; Cytotoxicity; Drug testing; In vitro; Naphthoquinones

Indexed keywords

10 ACETOXY N1 METHYLNAPHTH[F]INDAZOLE 4,9 QUINONE; 2 METHYL 5,8 DIHYDROXYBENZ[F]INDAZOLE 4,9 QUINONE; 3 BENZOYL 6,7 DIMETHYL 5,8 DIACETOXY N1 ETHYLBENZ[F]INDAZOLE 4,9 QUINONE; 3 METHYL N1 ETHYLBENZ[F]INDAZOLE 4,9 QUINONE; 5 BROMO N1 METHYLBENZ[F]INDAZOLE 4,9 QUINONE; 5 CHLORO 6 METHYL 8 HYDROXY N2 METHYLBENZ[F]INDAZOLE 4,9 QUINONE; 5 CHLORO N2 METHYLBENZ[F]INDAZOLE 4,9 QUINONE; 5 HYDROXY 7 METHYL N1 METHYLBENZ[F]INDAZOLE 4,9 QUINONE; 5 HYDROXY 8 CHLORO N1 METHYLBENZ[F]INDAZOLE 4,9 QUINONE; 5 HYDROXY N1 METHYLBENZ[F]INDAZOLE 4,9 QUINONE; 5 HYDROXY N2 METHYLBENZ[F]INDAZOLE 4,9 QUINONE; 5 METHOXY N1 METHYLBENZ[F]INDAZOLE 4,9 QUINONE; 5 METHYL N1 METHYLBENZ[F]INDAZOLE 4,9 QUINONE; 5,8 DIHYDROXY N1 ETHYLBENZ[F]INDAZOLE 4,9 QUINONE; 5,8 DIHYDROXYBENZ[F]INDAZOLE 4,9 QUINONE; 7 METHYL 5 METHOXY N1 METHYLBENZ[F]INDAZOLE 4,9 QUINONE; 7 METHYL N1 METHYLBENZ[F]INDAZOLE 4,9 QUINONE; 8 ACETOXY N1 METHYLBENZ[F]INDAZOLE 4,9 QUINONE; ANTIPROTOZOAL AGENT; BENZ[F]INDAZOLE 4,9 QUINONE; BENZINDAZOLE 4,9 QUINONE DERIVATIVE; N1 METHYLBENZ[F]INDAZOLE 4,9 QUINONE; N2 METHYLBENZ[F]INDAZOLE 4,9 QUINONE; NAPHTHINDAZOLE 4,9 QUINONE DERIVATIVE; QUINONE DERIVATIVE; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CECUM; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; DRUG STRUCTURE; DRUG SYNTHESIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; ILEUM; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; SCORING SYSTEM;

ANIMALS; CATTLE; CECAL DISEASES; CELL LINE; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; EPITHELIAL CELLS; GENES, T-CELL RECEPTOR ALPHA; HUMANS; ILEAL DISEASES; MICE; QUINONES;

EID: 0036920038     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkf199     Document Type: Article

References (30)

1. Laing, R. B. (1999). Nosocomial infections in patients with HIV disease. Journal of Hospital Infection 43, 179-85.
2. Ramratnam, B. & Flanigan, T. P. (1997). Cryptosporidiosis in persons with HIV infection. Postgraduate Medical Journal 73, 713-6.
3. Das, P. (1996). Cryptosporidium related diarrhoea. Indian Journal of Medical Research 104, 86-95.
4. Hoepelman, I. M. (1996). Human cryptosporidiosis. International Journal of STD and AIDS 7, Suppl. 1, 28-33.
5. Woods, K. M., Nesterenko, M. V. & Upton, S. J. (1996). Efficacy of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro. Annals of Tropical Medicine and Parasitology 90, 603-15.
6. Nelson, S. P., Lin, P. L., Miller, J., Katz, B. Z. & Gonzalez-Crussi, Z. (1999). Cryptosporidia enterocolitis in an immunocompetent infant treated with paromomycin. Clinical Pediatrics 38, 367-9.
7. Theodos, C. M., Griffiths, J. K., D'Onfro, J., Fairfield, A. & Tzipori, S. (1998). Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models. Antimicrobal Agents and Chemotherapy 42, 1959-65.
8. Smith, N. H., Cron, S., Valdez, L. M., Chappell, C. L. & White, A. C., Jr (1998). Combination drug therapy for cryptosporidiosis in AIDS. Journal of Infectious Diseases 178, 900-3.
9. Uip, D. E., Lima, A. L., Amato, V. S., Boulos, M., Neto, V. A. & Bem David, D. J. (1998). Roxithromycin treatment for diarrhoea caused by Cryptosporidium spp. in patients with AIDS. Jounal of Antimicrobial Chemotherapy 41, Suppl. B, 93-7.
10. Derouin, F. & Gangneux, J.-P. (1998). Changing patterns of disease and treatment of opportunistic parasitic infections in patients with AIDS. Current Opinion in Infectious Diseases 11, 711-6.
11. Laatsch, H. (1985). Über die Selektivit-dsat der Addition von Diazomethan an benzoid substituierte 1,4-Naphthochinone. Justus Liebigs Annalen der Chemie, 251-74.
12. Kayser, O., Kiderlen, A. F., Croft, S. L. & Laatsch, H. (2000). In vitro leishmanicidal activity of monomeric and dimeric naphthoquinones. Acta Tropica 76, 131-8.
13. Laatsch, H. (1986). Synthese dimerer und cyclo-trimerzer 1,4-anthrachinone. Justus Liebigs Annalen der Chemie, 839-58.
14. Woods, K. M., Nesterenko, M. V. & Upton, S. J. (1995). Development of a microtitre ELISA to quantify development of Cryptosporidium parvum in vitro. FEMS Microbiology Letters 128, 89-93.
15. Kayser, O., Waters, W. R., Woods, K. M., Upton, S. J., Keithly, J. S. & Kiderlen, A. F. (2001). Evaluation of in vitro and in vivo activity of aurones and related compounds against Cryptosporidium parvum. Planta Medica 67, 722-5.
16. Upton, S. J. (1997). In vitro cultivation. In Cryptosporidium, and Cryptosporidiosis, 1st edn (Fayer, R., Ed.), pp. 181-207. CRC Press, Boca Raton, FL, USA.
17. Upton, S. J., Tilley, M. & Brillhart, D. B. (1995). Effects of select medium supplements on in vitro development of Cryptosporidium parvum in HCT-8 cells. Journal of Clinical Microbiology 33, 371-5.
18. Waters, W. R. & Harp, J. A. (1996). Cryptosporidium parvum, in TCR-α- and TCR-δ-deficient mice. Infection and Immunity 64, 1854-7.
19. Harp, J. A., Chen, W. & Harmsen, A. G. (1992). Resistance of severe combined immunodeficient mice to infection with Cryptosporidium parvum: the importance of intestinal microflora. Infection and Immunity 60, 3509-12.
20. Waters, W. R., Reinhardt, T. A. & Harp, J. A. (1997). Oral administration of putrescine inhibits Cryptosporidium parvum infection of neonatal C57BL/6 mice and is independent of nitric oxide synthesis. Journal of Parasitology 83, 746-50.
21. Roehm, N. W., Rodgers, G. H., Hatfield, S. M. & Glasebrook, A. L. (1991). An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. Journal of Immunological Methods 142, 257-65.
22. Hazra, B., Pal, S. & Banerjee, A. (11992). New diospyrin derivatives with improved inhibitory activity towards Ehrlich ascites carcinoma. Medical Science and Research 22, 351-3.
23. Ellis, J. E. (1994). Coenzyme Q homologs in parasitic protozoa as targets for chemotherapeutic attack. Parasitology Today 10, 296-301.
24. Allemann, N. & Schneider, A. (2000). ATP production in isolated mitochondria of procyclic Trypanosoma brucei. Molecular and Biochemical Parasitology 111, 87-94.
25. Scheffler, I. E. (1999). Mitochondrial electron transport and oxidative phosphorylation. In Mitochondria, 1st edn (Scheffler, I. E., Ed.), pp. 1241-5. Wiley-Liss, New York, NY, USA.
26. Molina Portela, M. P., Fernandez Villamil, S. H., Perissinotti, L. J. & Stoppani, A. O. M. (1996). Redox cycling of o-naphthoquinones in trypanosomatids. Biochemical Pharmacology 52, 1875-82.
27. Croft, S. L., Evans, A. T. & Neal, R. A. (1985). The activity of plumbagin and other electron carriers against Leishmania donovani and Leishmania mexicana. Annals of Tropical Medicine and Parasitology 79, 651-3.
28. Riordan, C. E., Langreth, S. G., Sanchez, L. B., Kayser, O. & Keithly, J. S. (1999). Preliminary evidence for a mitochondrion in Cryptosporidium parvum: phylogeny and therapeutic implications. Journal of Eukaryotic Microbiology 46, 52-5S.
29. Srivastava, I. K., Rottenberg, H. & Vaidya, A. B. (1997). Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. Journal of Biological Chemistry 272, 3961-6.
30. Vercesi, A. E., Rodrigues, C. O., Uyemura, S. A., Zhong, L. & Moreno, S. N. J. (1998). Respiration and oxidative phosphorylation in the apicomplexan parasite Toxoplasma gondii. Journal of Biological Chemistry 273, 31040-7.